2750 Ethchlorvynol Ethchlorvynol is only found in individuals that have used or taken this drug. It is a sedative and hypnotic drug. It has been used to treat insomnia, but has been largely superseded and is only offered where an intolerance or allergy to other drugs exists. [Wikipedia]Although the exact mechanism of action is unknown, ethchlorvynol appears to depress the central nervous system in a manner similar to that of barbiturates. Barbiturates bind at a distinct binding sites associated with a Cl^- ionopore at the GABA_A receptor, increasing the duration of time for which the Cl^- ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged. 113-18-8 5281077 C7H9ClO 144.034190 < 25°C 28.5-30°C 1.43e-01 g/L Oral, rapidly absorbed from gastrointestinal tract. Although the exact mechanism of action is unknown, ethchlorvynol appears to depress the central nervous system in a manner similar to that of barbiturates. Barbiturates bind at a distinct binding sites associated with a Cl^- ionopore at the GABA_A receptor, increasing the duration of time for which the Cl^- ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged. About 90% of a dose is metabolized in the liver. Some ethchlorvynol may also be metabolized in the kidneys. Ethchlorvynol and metabolites undergo extensive enterohepatic recirculation. Half Life: Plasma half-life is approximately 10 to 20 hours, terminal half-life is 21-100 hours. No indication of carcinogenicity to humans (not listed by IARC). Used for short-term hypnotic therapy in the management of insomnia for periods of up to one week in duration; however, this medication generally has been replaced by other sedative-hypnotic agents. They cause slurred speech, disorientation and "drunken" behavior. They are physically and psychologically addictive. Symptoms of overdose include thrombocytopenia. 2009-07-21T20:26:15Z 2014-12-24T20:25:50Z Ethchlorvynol C07833 4882 Ethchlorvynol DB00189 true [H]\C(Cl)=C(\[H])C(O)(CC)C#C C7H9ClO InChI=1/C7H9ClO/c1-3-7(9,4-2)5-6-8/h1,5-6,9H,4H2,2H3/b6-5+ InChIKey=ZEHYJZXQEQOSON-AATRIKPKNA-N 144.599 144.034192617 Exogenous Liquid 1.8 HMDB14335 CHEMBL591 4444534 <p>Bayley, A. and McLamore, W.M.; U.S. Patent 2,746,900; May 22,1956; assigned to Chas.<br /> Pfizer &amp; Co., Inc.</p>